Angioimmunoblastic T-Cell Lymphoma

Mariko Yabe; Ahmet Dogan; Steven M Horwitz; Alison J Moskowitz

doi:10.1007/978-3-319-99716-2_5

Angioimmunoblastic T-Cell Lymphoma

Cancer Treat Res. 2019:176:99-126. doi: 10.1007/978-3-319-99716-2_5.

Authors

Mariko Yabe¹, Ahmet Dogan¹, Steven M Horwitz², Alison J Moskowitz³

Affiliations

¹ Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York City, USA.
² Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York City, USA.
³ Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York City, USA. moskowia@mskcc.org.

PMID: 30596215
DOI: 10.1007/978-3-319-99716-2_5

Abstract

Angioimmunoblastic T-cell lymphoma (AITL) is one of the most common types of T-cell lymphoma, representing about 15-20% of cases of peripheral T-cell lymphoma (PTCL). It is characterized by a unique clinical presentation and distinct pathologic and molecular features. Classes of drugs particularly active in AITL are emerging; however, treatment of relapsed and refractory disease remains a challenge. This chapter reviews the epidemiology, clinical presentation, pathogenesis, diagnosis, and treatment of AITL.

Keywords: Angioimmunoblastic T-cell lymphoma; Follicular helper T-cell; Pathology; Treatment.

MeSH terms

Humans
Immunoblastic Lymphadenopathy* / diagnosis
Immunoblastic Lymphadenopathy* / drug therapy
Lymphoma, T-Cell*
Lymphoma, T-Cell, Peripheral*